This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogenetics
Blood Cancer Journal Open Access 24 May 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukaemia. N Engl J Med 2008; 358: 1909–1918.
Bacher U, Haferlach C, Schnittger S, Kern W, Kroeger N, Zander AR et al. Interactive diagnostics in the indication to allogeneic SCT in AML. Review. Bone Marrow Transplant 2009; 43: 745–756.
Chevallier P, Delaunay J, Turlure P, Pigneux A, Hunault M, Garand R et al. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine and mitoxantrone in patients with CD33+ primary resistant or relapsed acute myeloid leukaemia. J Clin Oncol 2008; 26: 5192–5197.
Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation of cytogenetics, FAB subtype and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100: 59–66.
Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogeneous leukaemia with a normal karyotype. Blood 2005; 106: 3733–3739.
Meloni G, Mancini M, Gianfelici V, Martelli MP, Foa R, Falini B . Late relapse of acute myeloid leukaemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability. Haematologica 2009; 94: 298–300.
Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A et al. Compassionate-use of sorafenib in Flt3-ITD positive acute myeloid leukemia: sustained regression prior and post-allogeneic stem cell transplantation. Blood 2009; 113: 6567–6571.
Palmisano M, Grafone T, Ottaviani E, Testoni N, Baccarani M, Martineeli G . NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukaemia. Haematologica 2007; 92: 1268–1269.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chevallier, P., Prebet, T., Pigneux, A. et al. Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin. Leukemia 24, 467–469 (2010). https://doi.org/10.1038/leu.2009.214
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2009.214
This article is cited by
-
Treatment of Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
Current Hematologic Malignancy Reports (2014)
-
The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogenetics
Blood Cancer Journal (2013)
-
High-Dose Cytarabine (HD araC) in the Treatment of Leukemias: a Review
Current Hematologic Malignancy Reports (2013)
-
Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse
Annals of Hematology (2012)
-
Molecular markers in acute myeloid leukaemia
International Journal of Hematology (2012)